MedVadis Research Corporation
MedVadis Research Corporation
Waltham, Massachusetts, United States18 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | Diabetic Peripheral Neuropathic Pain | Active, not recruiting | Phase 3 | 2026-10-09 | NCT06696443 | |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arthritic joint disease, arthropathy, musculoskeletal system disorder, nutritional disorder, obesity disorder, osteoarthritis, overnutrition, rheumatic disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT07153471 | |
| A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-07 | NCT06653153 | |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-09-25 | NCT07035093 | |
| Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine | Ear Diseases, Nausea, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Photophobia, Sensation Disorders, Signs and Symptoms, Signs and Symptoms, Digestive, brain disorder, central nervous system disorder, eye disorder, headache disorder, hearing disorder, hyperacusis, hypnic headache, migraine disorder, nervous system disorder, otorhinolaryngologic disease, vision disorder | Recruiting | Phase 3 | 2026-09-24 | NCT04743141 | |
| Randomized Study in Children and Adolescents With Migraine: Acute Treatment | Ear Diseases, Nausea, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Photophobia, Sensation Disorders, Signs and Symptoms, Signs and Symptoms, Digestive, brain disorder, central nervous system disorder, eye disorder, headache disorder, hearing disorder, hyperacusis, hypnic headache, migraine disorder, nervous system disorder, otorhinolaryngologic disease, vision disorder | Recruiting | Phase 3 | 2026-09-24 | NCT04649242 | |
| A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | arthritic joint disease, arthropathy, musculoskeletal system disorder, osteoarthritis, osteoarthritis, knee, rheumatic disorder | Recruiting | Phase 2 | 2026-09-23 | NCT05986292 | |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-22 | NCT07392190 | |
| A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain | Chronic Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arthritic joint disease, arthropathy, musculoskeletal system disorder, osteoarthritis, osteoarthritis, knee, rheumatic disorder | Recruiting | Phase 2 | 2026-09-04 | NCT07641517 | |
| A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain | Back Pain, Chronic Pain, Low Back Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Recruiting | Phase 2 | 2026-09-04 | NCT07641504 | |
| A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-08-26 | NCT04437511 | |
| A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | Alzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-07-07 | NCT07602582 | |
| A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathic Pain | Recruiting | Phase 2 | 2026-07-07 | NCT07285018 | |
| A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-06-18 | NCT05738486 | |
| Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathic Pain | Recruiting | Phase 3 | 2026-06-15 | NCT06628908 | |
| A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | Headache, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Active, not recruiting | Phase 3 | 2026-02-27 | NCT04616326 | |
| A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | Headache, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Active, not recruiting | Phase 3 | 2026-01-26 | NCT03432286 | |
| A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-01-21 | NCT05026866 |